In a groundbreaking development, the interim analysis of the large multicenter Phase III VASE (Vascular Anomaly-Sirolimus Europe) trial, using sirolimus (Rapamune from Pfizer), to address slow-flow vascular malformations has been published in JCI Insight. This marks a significant milestone in the ongoing study and provides insight into the potential efficacy of this treatment.
